The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors

被引:4
作者
Metser, Ur [1 ,2 ]
Eshet, Yael [1 ,2 ]
Ortega, Claudia [1 ,2 ]
Veit-Haibach, Patrick [1 ,2 ]
Liu, Amy [3 ]
K. S. Wong, Rebecca [2 ,4 ]
机构
[1] Joint Dept Med Imaging Univ Hlth Network Mt Sinai, 610 Univ Ave,Suite 3-920, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, 610 Univ Ave,Suite 3-920, Toronto, ON M5G 2M9, Canada
[3] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON, Canada
[4] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada
关键词
Lu-177-DOTATATE; somatostatin; PET; Krenning score; therapy response; neuroendocrine; RADIONUCLIDE THERAPY;
D O I
10.1097/MNM.0000000000001488
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose To determine in a group of patients with progressive metastatic neuroendocrine tumors (PM-NETs) treated with Lu-177-DOTATATE whether a correlation exists between somatostatin receptor (SSTR)-2 expression in various tumors on baseline Ga-68-DOTATATE PET and their response to therapy. A secondary aim was to determine whether an association exists between tumor product of diameter (POD) and PET-derived Krenning score. Materials & methods Patients treated PM-NETs who had SSTR-2 overexpression (SSTR-RADS 5) on screening Ga-68-DOTATATE PET and CT at baseline and 3 months after therapy completion were included. Marker lesions on baseline CT were reassessed on CT after therapy using adapted Southwest Oncology Group solid tumor evaluation criteria. For each lesion, bidimensional diameter on CT and SSTR expression on PET (SSTR-RADS uptake score & PET-derived Krenning score) were recorded. Logistic regression models fitted through generalized estimating equations were used to assess for an association between SSTR expression and response to therapy, or lesion's POD. Results Forty-one patients with SSTR-RADS 5 PM-NETs treated with Lu-177-DOTATATE were included. There were 135 marker lesions (mean 3.2 lesions/patient) with Krenning score of 4 (n = 74), 3 (n = 44) or 2 (n = 17). There was no association found between SSTR-2 expression, as determined by SSTR-RADS uptake score or PET-derived Krenning score, and POD or response to therapy. Conclusion In patients with SSTR-RADS 5 PM-NETs treated with Lu-177-DOTATATE, there was similar response to therapy for all lesions with PET-generated Krenning score >= 2. No correlation was found between lesion's POD and level of tracer uptake.
引用
收藏
页码:73 / 77
页数:5
相关论文
共 15 条
  • [1] 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
    Bushnell, David L., Jr.
    O'Dorisio, Thomas M.
    O'Dorisio, M. Sue
    Menda, Yusuf
    Hicks, Rodney J.
    Van Cutsem, Eric
    Baulieu, Jean-Louis
    Borson-Chazot, Francoise
    Anthony, Lowell
    Benson, Al B.
    Oberg, Kjell
    Grossman, Ashley B.
    Connolly, Mary
    Bouterfa, Hakim
    Li, Yong
    Kacena, Katherine A.
    LaFrance, Norman
    Pauwels, Stanislas A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) : 1652 - 1659
  • [2] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [3] Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE
    Graf, Josephine
    Pape, Ulrich-Frank
    Jann, Henning
    Denecke, Timm
    Arsenic, Ruza
    Brenner, Winfried
    Pavel, Marianne
    Prasad, Vikas
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (04) : 881 - 894
  • [4] Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation
    Hofman, Michael S.
    Lau, W. F. Eddie
    Hicks, Rodney J.
    [J]. RADIOGRAPHICS, 2015, 35 (02) : 500 - 516
  • [5] 111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden
    Hope, Thomas A.
    Calais, Jeremie
    Zhang, Li
    Dieckmann, William
    Millo, Corina
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (09) : 1266 - 1269
  • [6] Krenning EP, 1999, ITAL J GASTROENTEROL, V31, pS219
  • [7] Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
    Kwekkeboom, Dik J.
    de Herder, Wouter W.
    Kam, Boen L.
    van Eijck, Casper H.
    van Essen, Martijn
    Kooij, Peter P.
    Feelders, Richard A.
    van Aken, Maarten O.
    Krenning, Eric P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2124 - 2130
  • [8] Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
    Ortega, Claudia
    Wong, Rebecca K. S.
    Schaefferkoetter, Josh
    Veit-Haibach, Patrick
    Myrehaug, Sten
    Juergens, Rosalyn
    Laidley, David
    Anconina, Reut
    Liu, Amy
    Metser, Ur
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (10) : 1406 - 1414
  • [9] 18F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria
    Ortega, Claudia
    Schaefferkoetter, Josh
    Veit-Haibach, Patrick
    Anconina, Reut
    Berlin, Alejandro
    Perlis, Nathan
    Metser, Ur
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (11) : 1615 - 1620
  • [10] Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
    Strosberg, J.
    El-Haddad, G.
    Wolin, E.
    Hendifar, A.
    Yao, J.
    Chasen, B.
    Mittra, E.
    Kunz, P. L.
    Kulke, M. H.
    Jacene, H.
    Bushnell, D.
    O'Dorisio, T. M.
    Baum, R. P.
    Kulkarni, H. R.
    Caplin, M.
    Lebtahi, R.
    Hobday, T.
    Delpassand, E.
    Van Cutsem, E.
    Benson, A.
    Srirajaskanthan, R.
    Pavel, M.
    Mora, J.
    Berlin, J.
    Grande, E.
    Reed, N.
    Seregni, E.
    Oberg, K.
    Sierra, M. Lopera
    Santoro, P.
    Thevenet, T.
    Erion, J. L.
    Ruszniewski, P.
    Kwekkeboom, D.
    Krenning, E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (02) : 125 - 135